Non-gyrA-mediated ciprofloxacin resistance in laboratory mutants of Streptococcus pneumoniae

被引:12
作者
Piddock, LJV
Jin, YF
Everett, MJ
机构
[1] Antimicrobial Agents Research Group, Department of Infection, University of Birmingham
关键词
D O I
10.1093/jac/39.5.609
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Two strains of Streptococcus pneumoniae, M4 (NCTC 7465, type strain) and M5 (clinical isolate), and their respective ciprofloxacin-resistant mutants, M4/C1, M5/C1 and M5/C3, were evaluated. All mutants were stable after one year's storage and all grew more slowly in Brain Heart Infusion broth than the parent. The MICs of ciprofloxacin, sparfloxacin and tosufloxacin were increased for the mutants of M4, whereas the mutants of M5 were less susceptible to ciprofloxacin only. The optimal bactericidal concentration (OBC) of each quinolone for all the strains was approximately ten-fold greater than the MIG. The OBCs for the mutants were increased for ciprofloxacin, but not for the other two quinolones. The DNA synthesis IC50 values of all quinolones correlated well with the MIC of each drug. AII quinolones accumulated rapidly within ail five strains; 10 mM magnesium chloride decreased the concentration of quinolone accumulated, but carbonyl cyanide m-chlorophenyl hydrazone had no effect. Mutant strains M4/C1, M5/C1 and M5/C3 accumulated less quinolone than their respective parent strains. DNA sequencing of those regions of gyrA and gyrB corresponding to the quinolone resistance-determining region in other bacteria did not reveal any differences between the parent and mutant strains.
引用
收藏
页码:609 / 615
页数:7
相关论文
共 28 条
[1]   SUSCEPTIBILITY OF PENICILLIN-SENSITIVE AND PENICILLIN-RESISTANT STRAINS OF STREPTOCOCCUS-PNEUMONIAE TO NEW ANTIMICROBIAL AGENTS, INCLUDING DAPTOMYCIN, TEICOPLANIN, CEFPODOXIME AND QUINOLONES [J].
APPELBAUM, PC ;
SPANGLER, SK ;
CROTTY, E ;
JACOBS, MR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 23 (04) :509-516
[2]  
Bernard Louis, 1995, Clin Microbiol Infect, V1, P60, DOI 10.1111/j.1469-0691.1995.tb00027.x
[3]   INVITRO ACTIVITY OF SPARFLOXACIN, A NEW QUINOLONE ANTIMICROBIAL AGENT [J].
COOPER, MA ;
ANDREWS, JM ;
ASHBY, JP ;
MATTHEWS, RS ;
WISE, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 (05) :667-676
[4]   EFFICACY AND SAFETY OF CIPROFLOXACIN IN PATIENTS WITH RESPIRATORY-INFECTIONS IN COMPARISON WITH AMOXICILLIN [J].
GLEADHILL, IC ;
FERGUSON, WP ;
LOWRY, RC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1986, 18 :133-138
[5]  
GOMBERT ME, 1984, ANTIMICROBIAL AGENTS, V26, P993
[6]  
HANSMAN D, 1967, LANCET, V2, P264
[7]   PHARMACOKINETICS OF CIPROFLOXACIN AFTER ORAL AND PARENTERAL ADMINISTRATION [J].
HOFFKEN, G ;
LODE, H ;
PRINZING, C ;
BORNER, K ;
KOEPPE, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 27 (03) :375-379
[8]  
KLUGMAN KP, 1990, CLIN MICROBIOLOGY RE, V31, P176
[9]  
KORNER RJ, 1994, BRIT MED J, V308, P191
[10]   ANALYSIS BY PCR AND DIRECT DNA-SEQUENCING OF GYRA MUTATIONS ASSOCIATED WITH FLUOROQUINOLONE RESISTANCE IN ENTEROCOCCUS-FAECALIS [J].
KORTEN, V ;
HUANG, WM ;
MURRAY, BE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (09) :2091-2094